1-[[2-(1-benzotriazolyl)-1-oxoethyl]amino]-3-cyclohexylthiourea

1-[[2-(1-benzotriazolyl)-1-oxoethyl]amino]-3-cyclohexylthiourea, often referred to by its abbreviation **BZT**, is a **potent and selective inhibitor of the enzyme cathepsin K**.

**Cathepsin K** is a lysosomal cysteine protease primarily found in osteoclasts, the cells responsible for bone resorption. It plays a crucial role in bone remodeling by breaking down bone matrix proteins.

**Importance in Research:**

* **Bone Diseases:** BZT's ability to inhibit cathepsin K makes it a valuable tool for studying bone diseases like osteoporosis, osteoarthritis, and Paget's disease. It can help researchers understand the role of cathepsin K in these diseases and potentially lead to new treatments.
* **Cancer Research:** Cathepsin K is also implicated in cancer metastasis. BZT's selectivity for cathepsin K makes it a promising candidate for investigating the role of this enzyme in tumor growth and spread.
* **Drug Development:** BZT is a lead compound for the development of new drugs targeting cathepsin K. The success of BZT in inhibiting cathepsin K has spurred the development of other inhibitors with improved properties, such as higher potency, better bioavailability, and reduced toxicity.

**Other Applications:**

* **Biomedical Research:** BZT can be used in research on various biological processes involving cathepsin K, such as inflammation, wound healing, and immune responses.
* **Materials Science:** Cathepsin K inhibitors, including BZT, are being explored for their potential applications in materials science, particularly in the development of biocompatible materials for bone regeneration.

**Key Points:**

* BZT is a potent and selective inhibitor of cathepsin K.
* Cathepsin K plays a significant role in bone remodeling and other biological processes.
* BZT's inhibition of cathepsin K makes it valuable for research in bone diseases, cancer, and drug development.

**Note:** BZT is a research tool and is not currently approved for clinical use.